Patent · US Active

Materials and methods for diagnosis and treatment of Alzheimer's disease

US10718785B2 · kind B2 · utility

3Cited by

2References

21Claims

0Family size

Assignee

ELECTROPHORETICS LIMITED · GB

Inventors

Ian Hugo Pike · London, GB
Claire Louise Russell · Cobham, GB
Malcolm Ward · Cobham, GB

Key dates

Filing date	Mar 17, 2016
Grant date	Jul 21, 2020
Priority date	—
Expiry date	Mar 17, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/2821
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Alzheimer's disease (AD) is the most common type of dementia in aging adults with the number of people living with AD projected to increase, making the search for treatments and tools to diagnose and measure disease progression increasingly urgent. In particular, ideal biomarkers for diagnosis of AD should not only have high specificity for disease versus non-disease and high sensitivity for distinguishing between disease types but also should be able to detect changes at a very early stage of the disease. Using microglia activation as an early event of AD's onset, the present inventors have identified a panel of biomarkers in CSF which has the potential to diagnose, stage and determine the likelihood of developing AD.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.